Heuser M, Herrmann R, Zoeller G, Hemmerlein B. Dynamics assesment of angiogenesis in renal cell carcinoma spheroids by intravital microscopy. J Urol. 2003;169:1267–70.
PubMed
Google Scholar
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.
CAS
PubMed
Google Scholar
Verine J, Colin D, Nheb M, Prapotnich D, Ploussard G, Cathelineau X, et al. Architectural patterns are a relevant morphologic grading system for clear cell renal cell carcinoma prognosis assessment: comparisons with WHO/ISUP grade and integrated staging systems. Am J Surg Pathol. 2018;42(4):423–41.
PubMed
Google Scholar
Schrader A, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU Int. 2006;97:461–5.
CAS
PubMed
Google Scholar
Colaci P, García M, Errecalde A, Inda A. Correlation between MVD and two prognostic factors: Fuhrman grade and Tumoral size, in clear cell renal cell carcinoma. J Cancer Sci Ther. 2012;4(10):313–6.
Google Scholar
Linehan MW, Bratslavsky G, Pinto P, Schmidt LS, Neckers L, Bottaro D, et al. Molecular diagnosis and therapy of kidney Cancer. Annu. Rev. Med. 2010;61:329–43.
CAS
PubMed
PubMed Central
Google Scholar
Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets. 2007;8:257–68.
CAS
PubMed
Google Scholar
Tamma R, Rutigliano M, Lucarelli G, Annese T, Ruggieri S, Cascardi E, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019;19:30026–2.
Google Scholar
Shibuya M. Vascular endothelial growth factor-dependent and independent regulation of angiogenesis. BMB Rep. 2008;41(4):278–86.
CAS
PubMed
Google Scholar
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-Angiogenic therapies. Genes Cancer. 2011;2(12):1097–105.
PubMed
PubMed Central
Google Scholar
Biselli-Chicote P, Oliveira A, Pavarino E, Goloni-Bertollo E. VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. J Cancer Res Clin Oncol. 2012;138(3):363–70.
CAS
PubMed
Google Scholar
Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B. Different isoform patterns of vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int. 2006;97(5):1102–8.
CAS
PubMed
Google Scholar
Vermeulen P, Gasparini G, Fox S, Toi M, Martin L, McCulloch F, et al. Quantification of angiogenesis in solid human tumors: an international consensus on methodology and criteria of evaluation. Eur J Cancer. 1996;32(14):2474–84.
Google Scholar
Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430–9.
CAS
PubMed
Google Scholar
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res. 2019;38:268–78.
PubMed
PubMed Central
Google Scholar
Xiaolei L, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31.
Google Scholar
Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021–31.
CAS
PubMed
Google Scholar
Priti S, Hegde J, Wallin J, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52:117–24.
Google Scholar
Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: An Immune Checkpoint Molecule. Adv Immunol. 2015;127:33–144.
CAS
PubMed
Google Scholar
Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A. 1997;94(21):11520–5.
CAS
PubMed
PubMed Central
Google Scholar
Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003;63(14):4107–11.
CAS
PubMed
Google Scholar
Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, et al. Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: focus on HLA-G/ILT2/ILT4. Oncoimmunology. 2017;6(9):13420–3.
Google Scholar
Tronik-Le Roux D, Renard J, Vérine J, Renault V, Tubacher E, LeMaoult J, Rouas-Freiss N, Deleuze JF, Desgrandschamps F, Carosella ED. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol Oncol. 2017;11:1561–78.
CAS
PubMed
PubMed Central
Google Scholar
Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, Rouas-Freiss N. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer. 2014;135(9):2107–17.
CAS
PubMed
Google Scholar
Zhang P, Guo X, Li J, Yu S, Wang L, Jiang G, et al. Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer. Oncotarget. 2015;6(15):13550–63.
PubMed
PubMed Central
Google Scholar
Zheng W, Aspelund A, Alitalo K. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest. 2014;124(3):878–87.
CAS
PubMed
PubMed Central
Google Scholar
Raica M, Jitariu AA, Cimpean Anca M. Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma. Anticancer Res. 2016;36(9):4427–36. https://doi.org/10.21873/anticanres.10986.
Article
CAS
PubMed
Google Scholar
Leah N, Cueni M, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol. 2008;6(3):109–22.
Google Scholar
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular Tumours. Eur Urol. 2016;70(1):93–105.
PubMed
Google Scholar
Weidner N, Semple J, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation and invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
CAS
PubMed
Google Scholar
Wittnebel S, Jalil A, Thiery J, DaRocha S, Viey E, Escudier B, Chouaib S, Caignard A. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Netw. 2005;16(2):123–7.
CAS
PubMed
Google Scholar
Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, −G3, and -G4 Isoforms Expressed as Nonmature Cell Surface Glycoproteins Inhibit NK and Antigen-Specific CTL Cytolysis. J Immunol. 2001;166:5018–26.
CAS
PubMed
Google Scholar
Hunt JS, Petroff M, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005;19:681–93.
CAS
PubMed
Google Scholar
Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer. 2010;46:3141–8.
CAS
PubMed
Google Scholar
Silvia P, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38:65–77.
Google Scholar
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini B, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57.
CAS
PubMed
PubMed Central
Google Scholar
Rakesh KJ. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–22.
Google Scholar
Zhang D, Lv FL, Wang GH. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci. 2018;22(16):5071–6.
CAS
PubMed
Google Scholar
Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, et al. Prognostic role of tumor necrosis, microvessel density, vascular endotelial growth factor and hipoxia inducible factor-1 alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol. 2008;21:447–55.
CAS
PubMed
Google Scholar
Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1:219–27.
CAS
PubMed
Google Scholar
Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 2006;9:209–23.
CAS
PubMed
Google Scholar
Gao A, Sun Y, Peng G. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy. Bioch et Bioph Acta Rev Cancer. 2018;1869(2):278–85.
CAS
Google Scholar
Carbone C, Piro G, Fassan M, Tamburrino A, Mina M, Zanotto M, et al. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget. 2015;6:13822–34.
PubMed
Google Scholar
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
CAS
PubMed
Google Scholar
Lin A, Xu HH, Xu DP, Zhang X, Wang Q, Yan WH. Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression. Hum Immunol. 2013;74(4):439–46.
CAS
PubMed
Google Scholar